Opinion

Video

First-Line HER2+ Metastatic Breast Cancer Trials in Focus

Author(s):

Tiffany A. Traina, MD,VK Gadi, MD, PhD

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

Related Videos
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
1 expert in this video
1 expert in this video
David Rimm, MD, PhD
Vered Stearns, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
1 expert in this video
Related Content
OncLive - stock.adobe.com
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast Cancer
November 27th 2024

Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Jairam Krishnamurthy, MD, FACP
November 22nd 2024

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center
November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC